



## IBA Signs Memorandum of Understanding to Install Proteus<sup>®</sup>ONE Proton Therapy System in Taiwan

### IBA's compact single-room PT solution to be installed at the Changhua Christian Hospital

**Louvain-la-Neuve, Belgium, October 16, 2012 - IBA (Ion Beam Applications SA)**, the global high-tech leader in the next generation of radiation therapy and diagnostics for the treatment of cancer, announces today that it has signed a Memorandum of Understanding (“MOU”) with the Changhua Christian Hospital in central Taiwan for the installation of its single-room proton therapy system, Proteus<sup>®</sup>ONE. The Proteus<sup>®</sup>ONE system has been developed by IBA to allow more patients globally to access proton therapy. Proteus<sup>®</sup>ONE is a smaller, less expensive, faster to install proton therapy solution, without compromising the latest in proton therapy technology, including Pencil Beam Scanning.

The MOU was signed in Taipei between the three parties involved in the project: the Changhua Christian Hospital, IBA and Chiu Ho Medical Systems Co. (part of the CHC Healthcare Group), IBA's agent in Taiwan. The three parties will collaborate towards the signing of a purchase agreement expected to become effective in the first part of 2013. The delivery of the equipment is expected to take place in 2014.

**Olivier Legrain, Chief Executive Officer of IBA commented:** “This MOU demonstrates IBA's continued success in Asia and further strengthens IBA's presence in the region. The Proteus<sup>®</sup>ONE has been developed by IBA to allow more patients in more countries to be able to access proton therapy, which is the most accurate form of radiation therapy available. We look forward to working with the Changhua Christian Hospital and for Taiwanese patients to be able to benefit from proton therapy.”

### Notes to Editors

#### About Proton Therapy

Proton Therapy is considered the most advanced and targeted cancer treatment due to its superior dose distribution and fewer side effects. Protons deposit the majority of their effective energy within a precisely controlled range, directly within the tumor, sparing healthy surrounding tissue. Higher doses can be delivered to the tumor without increasing the risk of



side effects and long-term complications, thereby improving patient outcomes and quality of life. To date, IBA has installed 12 operational proton beam systems, and has another 5 centers being installed as well as 5 others under construction around the world.

### **About Proteus<sup>®</sup>ONE\***

IBA Proteus<sup>®</sup>ONE is a compact single-room proton therapy solution. It benefits from the latest technologies of Proteus<sup>®</sup>PLUS, developed over the years with top clinical institutions worldwide. Proteus<sup>®</sup>ONE offers extended treatment solutions (IMPT, IGPT) enabling physicians to leverage on the clinical effectiveness offered by the proton beam precision. Proteus<sup>®</sup>ONE is IBA's response to make protons affordable: it is smaller, more affordable, easier to install, easier to operate and ultimately easier to finance. With Proteus<sup>®</sup>ONE, protons are possible for more patients worldwide.

### **About IBA**

IBA (Ion Beam Applications S.A.), is the global high-tech leader in next generation radiation therapy and diagnostics for the treatment of cancer. The Company's expertise lies in the development of next generation proton therapy technologies and radiopharmaceuticals that provide oncology care providers with premium quality services and equipment. This also includes IBA's leading fully integrated IntegraLab<sup>®</sup> radiopharmacy system and dosimetry advanced solutions for reliable Quality Assurance and increased patient safety.

Headquartered in Belgium and employing more than 1,200 people worldwide, IBA currently has installed systems across Europe and the US and is expanding into emerging markets. The Company is focused on building sustainable global growth for investors by providing solutions in the fight against cancer.

IBA is listed on the pan-European stock exchange EURONEXT. Further information can be found at: [www.iba-worldwide.com](http://www.iba-worldwide.com)

*\*Proteus<sup>®</sup>ONE is the brand name of a new configuration of the Proteus<sup>®</sup> 235, including some new developments subject to review by Competent Authorities (FDA, European Notified Bodies, et al.) before marketing.*

### **About Changhua Christian Hospital**

Changhua Christian Hospital (CCH) is a 1600 beds medical center located in central Taiwan. It is one of the country's premier academic medical centers and a major referral center for the Mid-South area and beyond. The hospital affiliates/subsidiaries provide a range of healthcare services including acute and critical inpatient care, ambulatory care, wellness and prevention programs. Website: [www.cch.org.tw](http://www.cch.org.tw)

### **About Chiu Ho Medical Systems**



Chiu Ho Medical System Co., Ltd. (CHC) is a leading Taiwan full healthcare service solution provider for high-end Radiation therapy, Radiology, Neurosurgery, Ophthalmology and Dentistry equipment. Since 2009, CHC installations of radiotherapy equipment have accounted for 80% of the total Taiwanese market. CHC is the exclusive master distributor for a portfolio of global brand name and has over 60+ certified experienced service engineers provide world class after sales support and maintenance services.

Website: [www.cyhc.com.tw](http://www.cyhc.com.tw)

**For further information please contact:**

**IBA**

Jean-Marc Bothy  
Chief Financial Officer  
+32 10 475 890  
[Investorrelations@iba-group.com](mailto:Investorrelations@iba-group.com)

Thomas Ralet  
Vice-President Corporate Communication  
+32 10 475 890  
[thomas.ralet@iba-group.com](mailto:thomas.ralet@iba-group.com)

**For media and investor enquiries:**

**M:Communications**

Mary-Jane Elliott, Amber Bielecka,  
Claire Dickinson  
+44 (0) 207 920 2333  
[IBA@mcomgroup.com](mailto:IBA@mcomgroup.com)